The EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra/RoActemra (tocilizumab),...
The National Institute of Health and Care Excellence has given its support for the use of RoActemra (tocilizumab) from Roche/Chugai,...
Genentech a member of the Roche Group announced that data from the Phase III GiACTA study, which evaluated Actemra(tocilizumab) in...
Genentech, a member of the Roche Group announced positive results from the Phase III study known as GiACTA , which...
Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, announced that the CHMP has adopted a positive opinion recommending the granting of a marketing authorization for its tocilizumab biosimilar candidate MSB 11456 referencing RoActemra (tocilizumab)
In final guidance, the National Institute of Health and Care Excellence has given its support for the use of RoActemra...
Genentech announced positive results from the Phase III GiACTA study, which evaluated Actemra (tocilizumab) in people with Giant Cell Arteritis...
Roche has announced that the European Commission (EC) has approved Actemra/RoActemra (tocilizumab)9in its subcutaneous version,) for the treatment of giant...
Genentech, a member of the Roche Group , announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the...
Genentech, announced that the FDA has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra (tocilizumab) for the treatment...